State Budget Cuts Force New Restrictions on HIV Drug Assistance Programs

The recent move by multiple state governments to scale back AIDS Drug Assistance Programs (ADAPs) marks a critical and concerning inflection point in the domestic response to the HIV epidemic. These programs, funded primarily through Part B of the Ryan White CARE Act, have long served as the final safety net for uninsured and underinsured individuals who do not qualify for Medicaid but cannot afford the high costs of antiretroviral therapy (ART). The implementation of new eligibility caps and the reintroduction of waitlists signal a departure from the 'Ending the HIV Epidemic' goals set by federal health authorities, which rely heavily on universal access to treatment to achieve viral suppression and prevent new transmissions.

The primary driver behind these restrictions is a perfect storm of fiscal pressures. As pandemic-era federal subsidies expire, state health departments are grappling with the rising costs of next-generation HIV therapies. While traditional daily oral regimens have seen some price stabilization through generic entry, the industry shift toward long-acting injectables—such as ViiV Healthcare’s Cabenuva—presents a new budgetary challenge. These innovative treatments offer significant quality-of-life improvements and better adherence rates, but their high list prices and the clinical infrastructure required for administration place an outsized burden on state-administered programs. Furthermore, the overall volume of patients requiring assistance continues to grow as individuals live longer with HIV and as economic volatility pushes more people out of employer-sponsored insurance.

“

Companies like Gilead Sciences and ViiV Healthcare are the dominant providers in this space, with drugs like Biktarvy and Dovato serving as the standard of care.

For the pharmaceutical industry, the tightening of ADAP eligibility creates a complex market dynamic. Companies like Gilead Sciences and ViiV Healthcare are the dominant providers in this space, with drugs like Biktarvy and Dovato serving as the standard of care. ADAPs are among the largest purchasers of these medications, often benefiting from significant mandatory and supplemental rebates. However, the reintroduction of waitlists—a phenomenon not seen at scale since the 2008-2011 economic downturn—could lead to a decrease in overall prescription volume. While manufacturers often provide patient assistance programs (PAPs) to bridge the gap, these are intended as temporary measures and lack the comprehensive support services, such as lab monitoring and case management, that are integrated into the ADAP framework.